Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NY-ESO-1-specific CD4+ T cells + ipilimumab in NY-ESO-1+ tumors
NCT02210104Phase 1Withdrawn
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Dec 2016
- Primary completion
- Dec 2019
01
Overview
Phase 1, open-label trial of NY-ESO-1-specific CD4+ T cells in melanoma, synovial sarcoma (SS) and Myxoid Round Cell Liposarcoma (MRCLS), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Maximum Tolerated Dose of Adoptively Transferred CD4 T Cells at 12 weeks. Planned start Dec 2016; status: withdrawn.
02
Drugs
NY-ESO-1-specific CD4+ T cells
03
Conditions
melanomasynovial sarcoma (SS)Myxoid Round Cell Liposarcoma (MRCLS)
Beyond the preview
Go deeper on NCT02210104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02210104.